<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35461084</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0046</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>235</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Drug and alcohol dependence</Title>
          <ISOAbbreviation>Drug Alcohol Depend</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness.</ArticleTitle>
        <Pagination>
          <StartPage>109440</StartPage>
          <MedlinePgn>109440</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.drugalcdep.2022.109440</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0376-8716(22)00177-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">During a COVID-19 outbreak in the congregate shelter system in Halifax, Nova Scotia, Canada, a healthcare team provided an emergency "safe supply" of medications and alcohol to facilitate isolation in COVID-19 hotel shelters for residents who use drugs and/or alcohol. We aimed to evaluate (a) substances and dosages provided, and (b) outcomes of the program.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed medical records of all COVID-19 isolation hotel shelter residents during May 2021. The primary outcome was successful completion of 14 days isolation, as directed by public health orders. Adverse events included (a) overdose; (b) intoxication; and (c) diversion, selling, or sharing of medications or alcohol.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventy-seven isolation hotel residents were assessed (mean age 42 ± 14 years; 24% women). Sixty-two (81%) residents were provided medications, alcohol, or cigarettes. Seventeen residents (22%) received opioid agonist treatment (methadone, buprenorphine, or slow-release oral morphine) and 27 (35%) received hydromorphone. Thirty-one (40%) residents received prescriptions stimulants. Six (8%) residents received benzodiazepines and forty-two (55%) received alcohol. Over 14 days, mean daily dosages increased of hydromorphone (45 ± 32 - 57 ± 42 mg), methylphenidate (51 ± 28 - 77 ± 37 mg), and alcohol (12.3 ± 7.6 - 13.0 ± 6.9 standard drinks). Six residents (8%) left isolation prematurely, but four returned. During 1059 person-days, there were zero overdoses. Documented concerns regarding intoxication occurred six times (0.005 events/person-day) and medication diversion/sharing three times (0.003 events/person-day).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">COVID-19 isolation hotel residents participating in an emergency safe supply and managed alcohol program experienced high rates of successful completion of 14 days isolation and low rates of adverse events.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Brothers</LastName>
            <ForeName>Thomas D</ForeName>
            <Initials>TD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine (General Internal Medicine &amp; Clinician-Investigator Program), Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; UCL Collaborative Centre for Inclusion Health, Institute of Epidemiology &amp; Health Care, University College London, London, UK. Electronic address: thomas.brothers@dal.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leaman</LastName>
            <ForeName>Malcolm</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bonn</LastName>
            <ForeName>Matthew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Canadian Association of People who Use Drugs, Dartmouth, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lewer</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>UCL Collaborative Centre for Inclusion Health, Institute of Epidemiology &amp; Health Care, University College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Atkinson</LastName>
            <ForeName>Jacqueline</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fraser</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada; Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Anesthesia, Pain Management &amp; Perioperative Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gillis</LastName>
            <ForeName>Amy</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gniewek</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Direction 180, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hawker</LastName>
            <ForeName>Leisha</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Direction 180, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hayman</LastName>
            <ForeName>Heather</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jorna</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Nova Pharmacy, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martell</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Direction 180, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Donnell</LastName>
            <ForeName>Tiffany</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rivers-Bowerman</LastName>
            <ForeName>Helen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Genge</LastName>
            <ForeName>Leah</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada; Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Direction 180, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Alcohol Depend</MedlineTA>
        <NlmUniqueID>7513587</NlmUniqueID>
        <ISSNLinking>0376-8716</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>3K9958V90M</RegistryNumber>
          <NameOfSubstance UI="D000431">Ethanol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q812464R06</RegistryNumber>
          <NameOfSubstance UI="D004091">Hydromorphone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062787" MajorTopicYN="Y">Drug Overdose</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000431" MajorTopicYN="N">Ethanol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006703" MajorTopicYN="Y">Homeless Persons</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006798" MajorTopicYN="N">Housing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004091" MajorTopicYN="N">Hydromorphone</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Drug addiction</Keyword>
        <Keyword MajorTopicYN="N">Harm reduction</Keyword>
        <Keyword MajorTopicYN="N">Needle-exchange programs</Keyword>
        <Keyword MajorTopicYN="N">Opiate substitution treatments</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
        <Keyword MajorTopicYN="N">Substance abuse, intravenous</Keyword>
        <Keyword MajorTopicYN="N">Substance use</Keyword>
        <Keyword MajorTopicYN="N">Substance-related disorders</Keyword>
      </KeywordList>
      <CoiStatement>MB reports personal fees from AbbVie, a pharmaceutical research and development company, and grants and personal fees from Gilead Sciences, a research-based biopharmaceutical company, outside of the submitted work. The other authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>20</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35461084</ArticleId>
        <ArticleId IdType="pmc">PMC8988445</ArticleId>
        <ArticleId IdType="doi">10.1016/j.drugalcdep.2022.109440</ArticleId>
        <ArticleId IdType="pii">S0376-8716(22)00177-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bonn M., Palayew A., Bartlett S., Brothers T.D., Touesnard N., Tyndall M. Addressing the syndemic of HIV, Hepatitis C, overdose, and COVID-19 among people who use drugs: the potential roles for decriminalization and safe supply. J. Stud. Alcohol Drugs. 2020;81(5):556–560. doi: 10.15288/jsad.2020.81.556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15288/jsad.2020.81.556</ArticleId>
            <ArticleId IdType="pubmed">33028465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomes T., Kitchen S.A., Murray R. Measuring the burden of opioid-related mortality in Ontario, Canada, during the COVID-19 pandemic. JAMA Netw. Open. 2021;4(5) doi: 10.1001/jamanetworkopen.2021.12865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2021.12865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunlop A., Lokuge B., Masters D., Sequeira M., Saul P., Dunlop G., et al.  Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct. J. 2020;17(1):26. doi: 10.1186/s12954-020-00370-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12954-020-00370-7</ArticleId>
            <ArticleId IdType="pmc">PMC7201394</ArticleId>
            <ArticleId IdType="pubmed">32375887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cowan E., Khan M.R., Shastry S., Edelman E.J. Conceptualizing the effects of the COVID-19 pandemic on people with opioid use disorder: an application of the social ecological model. Addict. Sci. Clin. Pr. 2021;16(1):4. doi: 10.1186/s13722-020-00210-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13722-020-00210-w</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomes, T., Murray, R., Kolla, G., Leece, P., Bansal, S., Besharah, J., et al., 2021. Changing circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic. Ontario Drug Policy Research Network; 2021 May [cited 2021a Sep 30]. Available from: 〈https://www.publichealthontario.ca/-/media/documents/c/2021/changing-circumstances-surrounding-opioid-related-deaths.pdf?sc_lang=en〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Ali F., Russell C., Nafeh F., Rehm J., LeBlanc S., Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada. Int. J. Drug Policy. 2021;93 doi: 10.1016/j.drugpo.2021.103237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2021.103237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewer D., Braithwaite I., Bullock M., Eyre M.T., White P.J., Aldridge R.W., et al.  COVID-19 among people experiencing homelessness in England: a modelling study. Lancet Respir. Med. 2020;8(12):1181–1191. doi: 10.1016/s2213-2600(20)30396-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s2213-2600(20)30396-9</ArticleId>
            <ArticleId IdType="pmc">PMC7511167</ArticleId>
            <ArticleId IdType="pubmed">32979308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perri M., Dosani N., Hwang S.W. COVID-19 and people experiencing homelessness: challenges and mitigation strategies. CMAJ. 2020;192(26):E716–E719. doi: 10.1503/cmaj.200834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.200834</ArticleId>
            <ArticleId IdType="pmc">PMC7828890</ArticleId>
            <ArticleId IdType="pubmed">32601252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BCCSU, 2020. Clinical Guidance Risk Mitigation in the Context of Dual Public Health Emergencies. 2020. Available from: https://www.bccsu.ca/overview-covid-19-risk-mitigation-interim-clinical-guidance/.</Citation>
        </Reference>
        <Reference>
          <Citation>Brar R., Bruneau J., Butt P., Goyer M., Lim R., Poulin G., et al. Medications and other clinical approaches to support physical distancing for people who use substances during the COVID-19 pandemic: national rapid guidance. Vancouver, B.C.: Canadian Research Initiative on Substance Misuse (CRISM); 2020 Jun [cited 2021 Oct 13]. Available from: 〈https://crism.ca/wp-content/uploads/2020/06/CRISM-Guidance-Medications-and-other-clinical-approaches-22062020-final.pdf〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Bach P., Robinson S., Sutherland C., Brar R. Innovative strategies to support physical distancing among individuals with active addiction. Lancet Psychiatry. 2020;7(9):731–733. doi: 10.1016/s2215-0366(20)30231-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s2215-0366(20)30231-5</ArticleId>
            <ArticleId IdType="pmc">PMC7255226</ArticleId>
            <ArticleId IdType="pubmed">32473096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyshka, E., Dong, K., Meador, K., Speed, K., Abele, B., LeBlanc, S., et al., 2020. Supporting people who use substances in shelter settings during the COVID‑19 pandemic: national rapid guidance. Edmonton, Alberta: Canadian Research Initiative on Substance Misuse (CRISM); 2020 May [cited 2021 Oct 13]. Available from: 〈https://crism.ca/wp-content/uploads/2020/06/CRISM-Guidance-Supporting-People-Who-Use-Substances-in-Emergency-Shelter-Settings-V1.pdf〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Bonn M., Palayew A., Bartlett S., Brothers T.D., Touesnard N., Tyndall M. “The times they are a-changin’”: addressing common misconceptions about the role of safe supply in north america’s overdose crisis. J. Stud. Alcohol Drugs. 2021;82(1):158–160. doi: 10.15288/jsad.2021.82.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15288/jsad.2021.82.158</ArticleId>
            <ArticleId IdType="pubmed">33573734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canadian Association of People Who Use Drugs (CAPUD)., 2019. Safe Supply Concept Document [Internet]. 2019 Feb. Available from: 10.5281/zenodo.5637607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5281/zenodo.5637607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hales, J., Kolla, G., Man, T., O’Reilly, E., Rai, N., Sereda, A., 2020. Safer Opioid Supply Programs (SOS): A Harm Reduction Informed Guiding Document for Primary Care Teams. 2020 [cited 2020 Apr 19]. 〈https://docs.google.com/document/d/1hXRmNaOTB60wbmNqhBi5P_xxktEZnXFDWKMkJMu5ALM/〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Tyndall M. An emergency response to the opioid overdose crisis in Canada: a regulated opioid distribution program. CMAJ. 2018;190(2):E35–E36. doi: 10.1503/cmaj.171060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.171060</ArticleId>
            <ArticleId IdType="pmc">PMC5770249</ArticleId>
            <ArticleId IdType="pubmed">29335260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyndall M. Safer opioid distribution in response to the COVID-19 pandemic. Int. J. Drug Policy. 2020;83 doi: 10.1016/j.drugpo.2020.102880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2020.102880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang J., Agliata J., Guarinieri M. COVID-19 - enacting a ‘new normal’ for people who use drugs. Int. J. Drug Policy. 2020;83 doi: 10.1016/j.drugpo.2020.102832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2020.102832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PHAC, 2021. Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and Stimulant-related Harms in Canada [Internet]. Ottawa: Public Health Agency of Canada; 2021 Dec [cited 2022 Jan 13]. Available from: https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/.</Citation>
        </Reference>
        <Reference>
          <Citation>Lapointe-Gagner, G. 2016. Heroin: it’s just not an East Coast thing [Internet]. DavidMcKie.com. 2016 [cited 2022 Jan 7]. Available from: http://www.davidmckie.com/heroin-its-just-not-an-east-coast-thing/.</Citation>
        </Reference>
        <Reference>
          <Citation>Glegg, S., McCrae, K., Kolla, G., Touesnard, N., Turnbull, J., Brothers, T.D., et al., 2022. “COVID just kind of opened a can of whoop-ass”: The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. Int. J. Drug Policy. doi:In press.</Citation>
        </Reference>
        <Reference>
          <Citation>Nosyk B., Slaunwhite A., Urbanoski K., Hongdilokkul N., Palis H., Lock K., et al.  Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol. BMJ Open. 2021;11(6) doi: 10.1136/bmjopen-2020–048353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2020–048353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young S., Kolla G., McCormack D., Campbell T., Leece P., Strike C., et al.  Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. Int. J. Drug Policy. 2022;102 doi: 10.1016/j.drugpo.2022.103601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2022.103601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNeil R., Fleming T., Mayer S., Barker A., Mansoor M., Betsos A., et al.  Implementation of safe supply alternatives during intersecting COVID-19 and overdose health emergencies in British Columbia, Canada, 2021. Am. J. Public Health. 2022:e1–e8. doi: 10.2105/ajph.2021.306692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2105/ajph.2021.306692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris M.T.H., Young S., Barocas J., Bayoumi A.M., Caudarella A., Laurence G., et al.  A descriptive comparison of substance use services in recovery and isolation sites for people experiencing homelessness during the COVID-19 pandemic, Boston and Toronto. Public Health Rep. 2021;136(5):532–537. doi: 10.1177/00333549211032974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/00333549211032974</ArticleId>
            <ArticleId IdType="pmc">PMC8361564</ArticleId>
            <ArticleId IdType="pubmed">34269625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scallan E., Bodkin C., Wiwcharuk J., O’Shea T., Lennox R. Finding stability amidst the COVID-19 pandemic: the impact of emergency temporary housing for people who use drugs. Drug Alcohol Rev. 2022;41(1):7–8. doi: 10.1111/dar.13335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dar.13335</ArticleId>
            <ArticleId IdType="pmc">PMC8444638</ArticleId>
            <ArticleId IdType="pubmed">34134176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lew B., Bodkin C., Lennox R., O’Shea T., Wiwcharuk G., Turner S.D. The impact of an integrated safer use space and safer supply program on non-fatal overdose among emergency shelter residents during a COVID-19 outbreak: a case study. Harm Reduct. J. 2022;19(29) doi: 10.1186/s12954-022-00614-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12954-022-00614-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuchs J.D., Carter H.C., Evans J., Graham-Squire D., Imbert E., Bloome J., et al.  Assessment of a hotel-based COVID-19 isolation and quarantine strategy for persons experiencing homelessness. JAMA Netw. Open. 2021;4(3) doi: 10.1001/jamanetworkopen.2021.0490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ristau J., Mehtani N., Gomez S., Nance M., Keller D., Surlyn C., et al.  Successful implementation of managed alcohol programs in the San Francisco Bay Area during the COVID-19 crisis. Subst. Abus. 2021;42(2):140–147. doi: 10.1080/08897077.2021.1892012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08897077.2021.1892012</ArticleId>
            <ArticleId IdType="pubmed">33848451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann. Intern Med. 2007;147(8):573–577. doi: 10.7326/0003-4819-147-8-200710160-00010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-147-8-200710160-00010</ArticleId>
            <ArticleId IdType="pubmed">17938396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahji A., Stephenson C., Tyo R., Hawken E.R., Seitz D.P. Prevalence of cannabis withdrawal symptoms among people with regular or dependent use of cannabinoids: a systematic review and meta-analysis. JAMA Netw. Open. 2020;3(4) doi: 10.1001/jamanetworkopen.2020.2370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2020.2370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacDonald, M., 2021. The COVID-Zero approach: Why Atlantic Canada excels at slowing the spread of COVID-19. CTV News [Internet]. 2021 May 1 [cited 2022 Jan 20]; Available from: https://atlantic.ctvnews.ca/the-covid-zero-approach-why-atlantic-canada-excels-at-slowing-the-spread-of-covid-19–1.5410217.</Citation>
        </Reference>
        <Reference>
          <Citation>Perri M., Kaminski N., Bonn M., Kolla G., Guta A., Bayoumi A.M., et al.  A qualitative study on overdose response in the era of COVID-19 and beyond: how to spot someone so they never have to use alone. Harm Reduct. J. 2021;18(1):85. doi: 10.1186/s12954-021-00530-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12954-021-00530-3</ArticleId>
            <ArticleId IdType="pmc">PMC8339679</ArticleId>
            <ArticleId IdType="pubmed">34353323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canadian Association for Safe Supply (CASS)., 2020. Informing your consent: Regarding issues of the safe supply options for opioids in the “Risk Mitigation in the Context of Dual Public Health Emergencies” guideline [Internet]. 2020 [cited 2021 Oct 13]. Available from: https://d3n8a8pro7vhmx.cloudfront.net/unitedforsafesupply/pages/1038/attachments/original/1590636393/Informing_Your_Consent_Regarding_Issues_of_the_Safe_Supply_Options_for_Opioids_in_the___Risk_Mitigation_in_the_Context_of_Dual_Public_Health_Emergencies__GuidelineBriefFinal.pdf?1590636393.</Citation>
        </Reference>
        <Reference>
          <Citation>NATIONAL OVERDOSE RESPONSE SERVICE (NORS) [Internet]. National overdose response service (nors). [cited 2021 Oct 13]. Available from: https://www.nors.ca.</Citation>
        </Reference>
        <Reference>
          <Citation>Standard Drink Calculator [Internet]. [cited 2021 Sep 30]. Available from: http://aodtool.cfar.uvic.ca/index-stddt.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Brothers T.D., Fraser J., MacAdam E., Morgan B., Webster D. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder. Drug Alcohol Rev. 2022;41(2):430–434. doi: 10.1111/dar.13365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dar.13365</ArticleId>
            <ArticleId IdType="pmc">PMC8814044</ArticleId>
            <ArticleId IdType="pubmed">34347327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonn M., Touesnard N., Cheng B., Pugliese M., Comeau E., Bodkin C., et al., 2021. Securing safe supply during COVID-19 and beyond: Scoping review and knowledge mobilization [Internet]. Ottawa: Canadian Institutes of Health Research; 2021 Jan [cited 2021 Oct 14]. Available from: 〈https://covid19mentalhealthresearch.ca/wp-content/uploads/2021/01/HERDER_CMH-KS-Safe-Supply-scoping-review_manuscript_2020–11-23_FINAL.pdf〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Oviedo-Joekes E., Guh D., Brissette S., Marchand K., MacDonald S., Lock K., et al.  Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):447–455. doi: 10.1001/jamapsychiatry.2016.0109. May 1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamapsychiatry.2016.0109</ArticleId>
            <ArticleId IdType="pubmed">27049826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fairbairn N., Ross J., Trew M., Meador K., Turnbull J., MacDonald S., et al.  Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ. 2019;191(38):E1049–E1056. doi: 10.1503/cmaj.190344. Sep 23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.190344</ArticleId>
            <ArticleId IdType="pmc">PMC6763328</ArticleId>
            <ArticleId IdType="pubmed">31548191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivsins A., Boyd J., Mayer S., Collins A., Sutherland C., Kerr T., et al.  “It’s helped me a lot, just like to stay alive”: a qualitative analysis of outcomes of a novel hydromorphone tablet distribution program in Vancouver, Canada. J. Urban Health. 2021;98(1):59–69. doi: 10.1007/s11524-020-00489-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11524-020-00489-9</ArticleId>
            <ArticleId IdType="pmc">PMC7592642</ArticleId>
            <ArticleId IdType="pubmed">33118145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivsins A., Boyd J., Mayer S., Collins A., Sutherland C., Kerr T., et al.  Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study. Drug Alcohol Depend. 2020;216 doi: 10.1016/j.drugalcdep.2020.108202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugalcdep.2020.108202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris M.T., Seliga R.K., Fairbairn N., Nolan S., Walley A.Y., Weinstein Z.M., et al.  Outcomes of Ottawa, Canada’s Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. Int. J. Drug Policy. 2021;98 doi: 10.1016/j.drugpo.2021.103400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2021.103400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell T., Zhao J., Pauly B., Chow C., Vallance K., Wettlaufer A., et al.  Trajectories of alcohol use and related harms for managed alcohol program participants over 12 months compared with local controls: a quasi-experimental study. Alcohol Alcohol. 2021;56(6):651–659. doi: 10.1093/alcalc/agaa134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/alcalc/agaa134</ArticleId>
            <ArticleId IdType="pubmed">33418568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell T., Pauly B. (Bernie), Chow C., Erickson R.A., Krysowaty B., Roemer A., et al.  Does managing the consumption of people with severe alcohol dependence reduce harm? A comparison of participants in six Canadian managed alcohol programs with locally recruited controls. Drug Alcohol Rev. 2018;37(S1):S159–S166. doi: 10.1111/dar.12618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dar.12618</ArticleId>
            <ArticleId IdType="pubmed">29027283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crabtree A., Latham N., Morgan R., Pauly B., Bungay V., Buxton J.A. Perceived harms and harm reduction strategies among people who drink non-beverage alcohol: community-based qualitative research in Vancouver, Canada. Int. J. Drug Policy. 2018;59:85–93. doi: 10.1016/j.drugpo.2018.06.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2018.06.020</ArticleId>
            <ArticleId IdType="pubmed">30071398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauly B. (Bernie), Vallance K., Wettlaufer A., Chow C., Brown R., Evans J., et al.  Community managed alcohol programs in Canada: overview of key dimensions and implementation. Drug Alcohol Rev. 2018;37(S1):S132–S139. doi: 10.1111/dar.12681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dar.12681</ArticleId>
            <ArticleId IdType="pubmed">29573059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brothers T.D., Fraser J., MacAdam E., Hickcox S., Genge L., O’Donnell T., et al.  Implementation and evaluation of a novel, unofficial, trainee-organized hospital addiction medicine consultation service. Subst. Abus. 2021;42(4):433–437. doi: 10.1080/08897077.2020.1856291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08897077.2020.1856291</ArticleId>
            <ArticleId IdType="pubmed">33332248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brothers T.D., Mosseler K., Kirkland S., Melanson P., Barrett L., Webster D. Unequal access to opioid agonist treatment and sterile injecting equipment among hospitalized patients with injection drug use-associated infective endocarditis. PLoS ONE. 2022;17(1) doi: 10.1371/journal.pone.0263156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0263156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schleihauf E., Crabtree K., Dohoo C., Fleming S., McPeake H., Bowes M. Concurrent monitoring of opioid prescribing practices and opioid-related deaths: the context in Nova Scotia, Canada. Health Promot Chronic Dis. Prev. Can. 2018;38(9):334–338. doi: 10.24095/hpcdp.38.9.05.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.24095/hpcdp.38.9.05</ArticleId>
            <ArticleId IdType="pmc">PMC6169707</ArticleId>
            <ArticleId IdType="pubmed">30226727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biggar E., Papamihali K., Leclerc P., Hyshka E., Graham B., Taylor M., et al.  Towards cross-Canada monitoring of the unregulated street drug supply. BMC Public Heal. 2021;21(1):1678. doi: 10.1186/s12889-021-11757-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12889-021-11757-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson M., Parmar A., Papamihali K., Weng A., Lock K., Buxton J.A. Investigating opioid preference to inform safe supply services: a cross sectional study. Int. J. Drug Policy. 2022;101 doi: 10.1016/j.drugpo.2021.103574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2021.103574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marchand K., Beaumont S., Westfall J., MacDonald S., Harrison S., Marsh D.C., et al.  Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst. Abus. Treat. Prev. Policy. 2019;14(1):37. doi: 10.1186/s13011-019-0227-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13011-019-0227-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brothers T.D., Bonn M. Patient-centred care in opioid agonist treatment could improve outcomes. CMAJ. 2019;191(17):E460–E461. doi: 10.1503/cmaj.190430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.190430</ArticleId>
            <ArticleId IdType="pmc">PMC6488477</ArticleId>
            <ArticleId IdType="pubmed">32392475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brothers T.D., Fraser J., Webster D. Caring for people who inject drugs when they are admitted to hospital. CMAJ. 2021;193(12):E423–E424. doi: 10.1503/cmaj.202124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.202124</ArticleId>
            <ArticleId IdType="pmc">PMC8096383</ArticleId>
            <ArticleId IdType="pubmed">33753366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimmel S.D., Bazzi A.R., Barocas J.A. Integrating harm reduction and clinical care: lessons from Covid-19 respite and recuperation facilities. J. Subst. Abus. Treat. 2020;118 doi: 10.1016/j.jsat.2020.108103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jsat.2020.108103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuertes R., Belo E., Merendeiro C., Curado A., Gautier D., Neto A., et al.  Lisbon’s COVID 19 response: harm reduction interventions for people who use alcohol and other drugs in emergency shelters. Harm Reduct. J. 2021;18(1):13. doi: 10.1186/s12954-021-00463-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12954-021-00463-x</ArticleId>
            <ArticleId IdType="pmc">PMC7829636</ArticleId>
            <ArticleId IdType="pubmed">33494726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcus T.S., Heese J., Scheibe A., Shelly S., Lalla S.X., Hugo J.F. Harm reduction in an emergency response to homelessness during South Africa’s COVID-19 lockdown. Harm Reduct. J. 2020;17(1):60. doi: 10.1186/s12954-020-00404-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12954-020-00404-0</ArticleId>
            <ArticleId IdType="pmc">PMC7443613</ArticleId>
            <ArticleId IdType="pubmed">32831083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pisani E. Tilting at windmills and the evidence base on injecting drug use. Lancet. 2010;376(9737):226–227. doi: 10.1016/s0140–6736(10)61132–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140–6736(10)61132–4</ArticleId>
            <ArticleId IdType="pubmed">20669403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gostin L.O., Powers M. What does social justice require for the public’s health? Public health ethics and policy imperatives. Health Aff. 2006;25(4):1053–1060. doi: 10.1377/hlthaff.25.4.1053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1377/hlthaff.25.4.1053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeBruin D., Liaschenko J., Marshall M.F. Social justice in pandemic preparedness. Am. J. Public Health. 2012;102(4):586–591. doi: 10.2105/ajph.2011.300483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2105/ajph.2011.300483</ArticleId>
            <ArticleId IdType="pmc">PMC3489368</ArticleId>
            <ArticleId IdType="pubmed">22397337</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35461084</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0046</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>235</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Drug and alcohol dependence</Title>
          <ISOAbbreviation>Drug Alcohol Depend</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness.</ArticleTitle>
        <Pagination>
          <StartPage>109440</StartPage>
          <MedlinePgn>109440</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.drugalcdep.2022.109440</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0376-8716(22)00177-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">During a COVID-19 outbreak in the congregate shelter system in Halifax, Nova Scotia, Canada, a healthcare team provided an emergency "safe supply" of medications and alcohol to facilitate isolation in COVID-19 hotel shelters for residents who use drugs and/or alcohol. We aimed to evaluate (a) substances and dosages provided, and (b) outcomes of the program.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed medical records of all COVID-19 isolation hotel shelter residents during May 2021. The primary outcome was successful completion of 14 days isolation, as directed by public health orders. Adverse events included (a) overdose; (b) intoxication; and (c) diversion, selling, or sharing of medications or alcohol.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventy-seven isolation hotel residents were assessed (mean age 42 ± 14 years; 24% women). Sixty-two (81%) residents were provided medications, alcohol, or cigarettes. Seventeen residents (22%) received opioid agonist treatment (methadone, buprenorphine, or slow-release oral morphine) and 27 (35%) received hydromorphone. Thirty-one (40%) residents received prescriptions stimulants. Six (8%) residents received benzodiazepines and forty-two (55%) received alcohol. Over 14 days, mean daily dosages increased of hydromorphone (45 ± 32 - 57 ± 42 mg), methylphenidate (51 ± 28 - 77 ± 37 mg), and alcohol (12.3 ± 7.6 - 13.0 ± 6.9 standard drinks). Six residents (8%) left isolation prematurely, but four returned. During 1059 person-days, there were zero overdoses. Documented concerns regarding intoxication occurred six times (0.005 events/person-day) and medication diversion/sharing three times (0.003 events/person-day).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">COVID-19 isolation hotel residents participating in an emergency safe supply and managed alcohol program experienced high rates of successful completion of 14 days isolation and low rates of adverse events.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Brothers</LastName>
            <ForeName>Thomas D</ForeName>
            <Initials>TD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine (General Internal Medicine &amp; Clinician-Investigator Program), Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; UCL Collaborative Centre for Inclusion Health, Institute of Epidemiology &amp; Health Care, University College London, London, UK. Electronic address: thomas.brothers@dal.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leaman</LastName>
            <ForeName>Malcolm</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bonn</LastName>
            <ForeName>Matthew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Canadian Association of People who Use Drugs, Dartmouth, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lewer</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>UCL Collaborative Centre for Inclusion Health, Institute of Epidemiology &amp; Health Care, University College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Atkinson</LastName>
            <ForeName>Jacqueline</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fraser</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada; Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Anesthesia, Pain Management &amp; Perioperative Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gillis</LastName>
            <ForeName>Amy</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gniewek</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Direction 180, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hawker</LastName>
            <ForeName>Leisha</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Direction 180, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hayman</LastName>
            <ForeName>Heather</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jorna</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Nova Pharmacy, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martell</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Direction 180, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Donnell</LastName>
            <ForeName>Tiffany</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rivers-Bowerman</LastName>
            <ForeName>Helen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Genge</LastName>
            <ForeName>Leah</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>North End Community Health Centre, Halifax, Nova Scotia, Canada; Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Direction 180, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Alcohol Depend</MedlineTA>
        <NlmUniqueID>7513587</NlmUniqueID>
        <ISSNLinking>0376-8716</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>3K9958V90M</RegistryNumber>
          <NameOfSubstance UI="D000431">Ethanol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q812464R06</RegistryNumber>
          <NameOfSubstance UI="D004091">Hydromorphone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062787" MajorTopicYN="Y">Drug Overdose</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000431" MajorTopicYN="N">Ethanol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006703" MajorTopicYN="Y">Homeless Persons</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006798" MajorTopicYN="N">Housing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004091" MajorTopicYN="N">Hydromorphone</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Drug addiction</Keyword>
        <Keyword MajorTopicYN="N">Harm reduction</Keyword>
        <Keyword MajorTopicYN="N">Needle-exchange programs</Keyword>
        <Keyword MajorTopicYN="N">Opiate substitution treatments</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
        <Keyword MajorTopicYN="N">Substance abuse, intravenous</Keyword>
        <Keyword MajorTopicYN="N">Substance use</Keyword>
        <Keyword MajorTopicYN="N">Substance-related disorders</Keyword>
      </KeywordList>
      <CoiStatement>MB reports personal fees from AbbVie, a pharmaceutical research and development company, and grants and personal fees from Gilead Sciences, a research-based biopharmaceutical company, outside of the submitted work. The other authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>20</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35461084</ArticleId>
        <ArticleId IdType="pmc">PMC8988445</ArticleId>
        <ArticleId IdType="doi">10.1016/j.drugalcdep.2022.109440</ArticleId>
        <ArticleId IdType="pii">S0376-8716(22)00177-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bonn M., Palayew A., Bartlett S., Brothers T.D., Touesnard N., Tyndall M. Addressing the syndemic of HIV, Hepatitis C, overdose, and COVID-19 among people who use drugs: the potential roles for decriminalization and safe supply. J. Stud. Alcohol Drugs. 2020;81(5):556–560. doi: 10.15288/jsad.2020.81.556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15288/jsad.2020.81.556</ArticleId>
            <ArticleId IdType="pubmed">33028465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomes T., Kitchen S.A., Murray R. Measuring the burden of opioid-related mortality in Ontario, Canada, during the COVID-19 pandemic. JAMA Netw. Open. 2021;4(5) doi: 10.1001/jamanetworkopen.2021.12865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2021.12865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunlop A., Lokuge B., Masters D., Sequeira M., Saul P., Dunlop G., et al.  Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct. J. 2020;17(1):26. doi: 10.1186/s12954-020-00370-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12954-020-00370-7</ArticleId>
            <ArticleId IdType="pmc">PMC7201394</ArticleId>
            <ArticleId IdType="pubmed">32375887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cowan E., Khan M.R., Shastry S., Edelman E.J. Conceptualizing the effects of the COVID-19 pandemic on people with opioid use disorder: an application of the social ecological model. Addict. Sci. Clin. Pr. 2021;16(1):4. doi: 10.1186/s13722-020-00210-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13722-020-00210-w</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomes, T., Murray, R., Kolla, G., Leece, P., Bansal, S., Besharah, J., et al., 2021. Changing circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic. Ontario Drug Policy Research Network; 2021 May [cited 2021a Sep 30]. Available from: 〈https://www.publichealthontario.ca/-/media/documents/c/2021/changing-circumstances-surrounding-opioid-related-deaths.pdf?sc_lang=en〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Ali F., Russell C., Nafeh F., Rehm J., LeBlanc S., Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada. Int. J. Drug Policy. 2021;93 doi: 10.1016/j.drugpo.2021.103237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2021.103237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewer D., Braithwaite I., Bullock M., Eyre M.T., White P.J., Aldridge R.W., et al.  COVID-19 among people experiencing homelessness in England: a modelling study. Lancet Respir. Med. 2020;8(12):1181–1191. doi: 10.1016/s2213-2600(20)30396-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s2213-2600(20)30396-9</ArticleId>
            <ArticleId IdType="pmc">PMC7511167</ArticleId>
            <ArticleId IdType="pubmed">32979308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perri M., Dosani N., Hwang S.W. COVID-19 and people experiencing homelessness: challenges and mitigation strategies. CMAJ. 2020;192(26):E716–E719. doi: 10.1503/cmaj.200834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.200834</ArticleId>
            <ArticleId IdType="pmc">PMC7828890</ArticleId>
            <ArticleId IdType="pubmed">32601252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BCCSU, 2020. Clinical Guidance Risk Mitigation in the Context of Dual Public Health Emergencies. 2020. Available from: https://www.bccsu.ca/overview-covid-19-risk-mitigation-interim-clinical-guidance/.</Citation>
        </Reference>
        <Reference>
          <Citation>Brar R., Bruneau J., Butt P., Goyer M., Lim R., Poulin G., et al. Medications and other clinical approaches to support physical distancing for people who use substances during the COVID-19 pandemic: national rapid guidance. Vancouver, B.C.: Canadian Research Initiative on Substance Misuse (CRISM); 2020 Jun [cited 2021 Oct 13]. Available from: 〈https://crism.ca/wp-content/uploads/2020/06/CRISM-Guidance-Medications-and-other-clinical-approaches-22062020-final.pdf〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Bach P., Robinson S., Sutherland C., Brar R. Innovative strategies to support physical distancing among individuals with active addiction. Lancet Psychiatry. 2020;7(9):731–733. doi: 10.1016/s2215-0366(20)30231-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s2215-0366(20)30231-5</ArticleId>
            <ArticleId IdType="pmc">PMC7255226</ArticleId>
            <ArticleId IdType="pubmed">32473096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyshka, E., Dong, K., Meador, K., Speed, K., Abele, B., LeBlanc, S., et al., 2020. Supporting people who use substances in shelter settings during the COVID‑19 pandemic: national rapid guidance. Edmonton, Alberta: Canadian Research Initiative on Substance Misuse (CRISM); 2020 May [cited 2021 Oct 13]. Available from: 〈https://crism.ca/wp-content/uploads/2020/06/CRISM-Guidance-Supporting-People-Who-Use-Substances-in-Emergency-Shelter-Settings-V1.pdf〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Bonn M., Palayew A., Bartlett S., Brothers T.D., Touesnard N., Tyndall M. “The times they are a-changin’”: addressing common misconceptions about the role of safe supply in north america’s overdose crisis. J. Stud. Alcohol Drugs. 2021;82(1):158–160. doi: 10.15288/jsad.2021.82.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15288/jsad.2021.82.158</ArticleId>
            <ArticleId IdType="pubmed">33573734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canadian Association of People Who Use Drugs (CAPUD)., 2019. Safe Supply Concept Document [Internet]. 2019 Feb. Available from: 10.5281/zenodo.5637607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5281/zenodo.5637607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hales, J., Kolla, G., Man, T., O’Reilly, E., Rai, N., Sereda, A., 2020. Safer Opioid Supply Programs (SOS): A Harm Reduction Informed Guiding Document for Primary Care Teams. 2020 [cited 2020 Apr 19]. 〈https://docs.google.com/document/d/1hXRmNaOTB60wbmNqhBi5P_xxktEZnXFDWKMkJMu5ALM/〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Tyndall M. An emergency response to the opioid overdose crisis in Canada: a regulated opioid distribution program. CMAJ. 2018;190(2):E35–E36. doi: 10.1503/cmaj.171060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.171060</ArticleId>
            <ArticleId IdType="pmc">PMC5770249</ArticleId>
            <ArticleId IdType="pubmed">29335260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyndall M. Safer opioid distribution in response to the COVID-19 pandemic. Int. J. Drug Policy. 2020;83 doi: 10.1016/j.drugpo.2020.102880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2020.102880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang J., Agliata J., Guarinieri M. COVID-19 - enacting a ‘new normal’ for people who use drugs. Int. J. Drug Policy. 2020;83 doi: 10.1016/j.drugpo.2020.102832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2020.102832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PHAC, 2021. Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and Stimulant-related Harms in Canada [Internet]. Ottawa: Public Health Agency of Canada; 2021 Dec [cited 2022 Jan 13]. Available from: https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/.</Citation>
        </Reference>
        <Reference>
          <Citation>Lapointe-Gagner, G. 2016. Heroin: it’s just not an East Coast thing [Internet]. DavidMcKie.com. 2016 [cited 2022 Jan 7]. Available from: http://www.davidmckie.com/heroin-its-just-not-an-east-coast-thing/.</Citation>
        </Reference>
        <Reference>
          <Citation>Glegg, S., McCrae, K., Kolla, G., Touesnard, N., Turnbull, J., Brothers, T.D., et al., 2022. “COVID just kind of opened a can of whoop-ass”: The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. Int. J. Drug Policy. doi:In press.</Citation>
        </Reference>
        <Reference>
          <Citation>Nosyk B., Slaunwhite A., Urbanoski K., Hongdilokkul N., Palis H., Lock K., et al.  Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol. BMJ Open. 2021;11(6) doi: 10.1136/bmjopen-2020–048353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2020–048353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young S., Kolla G., McCormack D., Campbell T., Leece P., Strike C., et al.  Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. Int. J. Drug Policy. 2022;102 doi: 10.1016/j.drugpo.2022.103601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2022.103601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNeil R., Fleming T., Mayer S., Barker A., Mansoor M., Betsos A., et al.  Implementation of safe supply alternatives during intersecting COVID-19 and overdose health emergencies in British Columbia, Canada, 2021. Am. J. Public Health. 2022:e1–e8. doi: 10.2105/ajph.2021.306692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2105/ajph.2021.306692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris M.T.H., Young S., Barocas J., Bayoumi A.M., Caudarella A., Laurence G., et al.  A descriptive comparison of substance use services in recovery and isolation sites for people experiencing homelessness during the COVID-19 pandemic, Boston and Toronto. Public Health Rep. 2021;136(5):532–537. doi: 10.1177/00333549211032974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/00333549211032974</ArticleId>
            <ArticleId IdType="pmc">PMC8361564</ArticleId>
            <ArticleId IdType="pubmed">34269625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scallan E., Bodkin C., Wiwcharuk J., O’Shea T., Lennox R. Finding stability amidst the COVID-19 pandemic: the impact of emergency temporary housing for people who use drugs. Drug Alcohol Rev. 2022;41(1):7–8. doi: 10.1111/dar.13335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dar.13335</ArticleId>
            <ArticleId IdType="pmc">PMC8444638</ArticleId>
            <ArticleId IdType="pubmed">34134176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lew B., Bodkin C., Lennox R., O’Shea T., Wiwcharuk G., Turner S.D. The impact of an integrated safer use space and safer supply program on non-fatal overdose among emergency shelter residents during a COVID-19 outbreak: a case study. Harm Reduct. J. 2022;19(29) doi: 10.1186/s12954-022-00614-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12954-022-00614-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuchs J.D., Carter H.C., Evans J., Graham-Squire D., Imbert E., Bloome J., et al.  Assessment of a hotel-based COVID-19 isolation and quarantine strategy for persons experiencing homelessness. JAMA Netw. Open. 2021;4(3) doi: 10.1001/jamanetworkopen.2021.0490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ristau J., Mehtani N., Gomez S., Nance M., Keller D., Surlyn C., et al.  Successful implementation of managed alcohol programs in the San Francisco Bay Area during the COVID-19 crisis. Subst. Abus. 2021;42(2):140–147. doi: 10.1080/08897077.2021.1892012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08897077.2021.1892012</ArticleId>
            <ArticleId IdType="pubmed">33848451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann. Intern Med. 2007;147(8):573–577. doi: 10.7326/0003-4819-147-8-200710160-00010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-147-8-200710160-00010</ArticleId>
            <ArticleId IdType="pubmed">17938396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahji A., Stephenson C., Tyo R., Hawken E.R., Seitz D.P. Prevalence of cannabis withdrawal symptoms among people with regular or dependent use of cannabinoids: a systematic review and meta-analysis. JAMA Netw. Open. 2020;3(4) doi: 10.1001/jamanetworkopen.2020.2370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2020.2370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacDonald, M., 2021. The COVID-Zero approach: Why Atlantic Canada excels at slowing the spread of COVID-19. CTV News [Internet]. 2021 May 1 [cited 2022 Jan 20]; Available from: https://atlantic.ctvnews.ca/the-covid-zero-approach-why-atlantic-canada-excels-at-slowing-the-spread-of-covid-19–1.5410217.</Citation>
        </Reference>
        <Reference>
          <Citation>Perri M., Kaminski N., Bonn M., Kolla G., Guta A., Bayoumi A.M., et al.  A qualitative study on overdose response in the era of COVID-19 and beyond: how to spot someone so they never have to use alone. Harm Reduct. J. 2021;18(1):85. doi: 10.1186/s12954-021-00530-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12954-021-00530-3</ArticleId>
            <ArticleId IdType="pmc">PMC8339679</ArticleId>
            <ArticleId IdType="pubmed">34353323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canadian Association for Safe Supply (CASS)., 2020. Informing your consent: Regarding issues of the safe supply options for opioids in the “Risk Mitigation in the Context of Dual Public Health Emergencies” guideline [Internet]. 2020 [cited 2021 Oct 13]. Available from: https://d3n8a8pro7vhmx.cloudfront.net/unitedforsafesupply/pages/1038/attachments/original/1590636393/Informing_Your_Consent_Regarding_Issues_of_the_Safe_Supply_Options_for_Opioids_in_the___Risk_Mitigation_in_the_Context_of_Dual_Public_Health_Emergencies__GuidelineBriefFinal.pdf?1590636393.</Citation>
        </Reference>
        <Reference>
          <Citation>NATIONAL OVERDOSE RESPONSE SERVICE (NORS) [Internet]. National overdose response service (nors). [cited 2021 Oct 13]. Available from: https://www.nors.ca.</Citation>
        </Reference>
        <Reference>
          <Citation>Standard Drink Calculator [Internet]. [cited 2021 Sep 30]. Available from: http://aodtool.cfar.uvic.ca/index-stddt.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Brothers T.D., Fraser J., MacAdam E., Morgan B., Webster D. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder. Drug Alcohol Rev. 2022;41(2):430–434. doi: 10.1111/dar.13365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dar.13365</ArticleId>
            <ArticleId IdType="pmc">PMC8814044</ArticleId>
            <ArticleId IdType="pubmed">34347327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonn M., Touesnard N., Cheng B., Pugliese M., Comeau E., Bodkin C., et al., 2021. Securing safe supply during COVID-19 and beyond: Scoping review and knowledge mobilization [Internet]. Ottawa: Canadian Institutes of Health Research; 2021 Jan [cited 2021 Oct 14]. Available from: 〈https://covid19mentalhealthresearch.ca/wp-content/uploads/2021/01/HERDER_CMH-KS-Safe-Supply-scoping-review_manuscript_2020–11-23_FINAL.pdf〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Oviedo-Joekes E., Guh D., Brissette S., Marchand K., MacDonald S., Lock K., et al.  Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):447–455. doi: 10.1001/jamapsychiatry.2016.0109. May 1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamapsychiatry.2016.0109</ArticleId>
            <ArticleId IdType="pubmed">27049826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fairbairn N., Ross J., Trew M., Meador K., Turnbull J., MacDonald S., et al.  Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ. 2019;191(38):E1049–E1056. doi: 10.1503/cmaj.190344. Sep 23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.190344</ArticleId>
            <ArticleId IdType="pmc">PMC6763328</ArticleId>
            <ArticleId IdType="pubmed">31548191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivsins A., Boyd J., Mayer S., Collins A., Sutherland C., Kerr T., et al.  “It’s helped me a lot, just like to stay alive”: a qualitative analysis of outcomes of a novel hydromorphone tablet distribution program in Vancouver, Canada. J. Urban Health. 2021;98(1):59–69. doi: 10.1007/s11524-020-00489-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11524-020-00489-9</ArticleId>
            <ArticleId IdType="pmc">PMC7592642</ArticleId>
            <ArticleId IdType="pubmed">33118145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivsins A., Boyd J., Mayer S., Collins A., Sutherland C., Kerr T., et al.  Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study. Drug Alcohol Depend. 2020;216 doi: 10.1016/j.drugalcdep.2020.108202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugalcdep.2020.108202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris M.T., Seliga R.K., Fairbairn N., Nolan S., Walley A.Y., Weinstein Z.M., et al.  Outcomes of Ottawa, Canada’s Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. Int. J. Drug Policy. 2021;98 doi: 10.1016/j.drugpo.2021.103400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2021.103400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell T., Zhao J., Pauly B., Chow C., Vallance K., Wettlaufer A., et al.  Trajectories of alcohol use and related harms for managed alcohol program participants over 12 months compared with local controls: a quasi-experimental study. Alcohol Alcohol. 2021;56(6):651–659. doi: 10.1093/alcalc/agaa134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/alcalc/agaa134</ArticleId>
            <ArticleId IdType="pubmed">33418568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell T., Pauly B. (Bernie), Chow C., Erickson R.A., Krysowaty B., Roemer A., et al.  Does managing the consumption of people with severe alcohol dependence reduce harm? A comparison of participants in six Canadian managed alcohol programs with locally recruited controls. Drug Alcohol Rev. 2018;37(S1):S159–S166. doi: 10.1111/dar.12618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dar.12618</ArticleId>
            <ArticleId IdType="pubmed">29027283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crabtree A., Latham N., Morgan R., Pauly B., Bungay V., Buxton J.A. Perceived harms and harm reduction strategies among people who drink non-beverage alcohol: community-based qualitative research in Vancouver, Canada. Int. J. Drug Policy. 2018;59:85–93. doi: 10.1016/j.drugpo.2018.06.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2018.06.020</ArticleId>
            <ArticleId IdType="pubmed">30071398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauly B. (Bernie), Vallance K., Wettlaufer A., Chow C., Brown R., Evans J., et al.  Community managed alcohol programs in Canada: overview of key dimensions and implementation. Drug Alcohol Rev. 2018;37(S1):S132–S139. doi: 10.1111/dar.12681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dar.12681</ArticleId>
            <ArticleId IdType="pubmed">29573059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brothers T.D., Fraser J., MacAdam E., Hickcox S., Genge L., O’Donnell T., et al.  Implementation and evaluation of a novel, unofficial, trainee-organized hospital addiction medicine consultation service. Subst. Abus. 2021;42(4):433–437. doi: 10.1080/08897077.2020.1856291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08897077.2020.1856291</ArticleId>
            <ArticleId IdType="pubmed">33332248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brothers T.D., Mosseler K., Kirkland S., Melanson P., Barrett L., Webster D. Unequal access to opioid agonist treatment and sterile injecting equipment among hospitalized patients with injection drug use-associated infective endocarditis. PLoS ONE. 2022;17(1) doi: 10.1371/journal.pone.0263156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0263156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schleihauf E., Crabtree K., Dohoo C., Fleming S., McPeake H., Bowes M. Concurrent monitoring of opioid prescribing practices and opioid-related deaths: the context in Nova Scotia, Canada. Health Promot Chronic Dis. Prev. Can. 2018;38(9):334–338. doi: 10.24095/hpcdp.38.9.05.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.24095/hpcdp.38.9.05</ArticleId>
            <ArticleId IdType="pmc">PMC6169707</ArticleId>
            <ArticleId IdType="pubmed">30226727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biggar E., Papamihali K., Leclerc P., Hyshka E., Graham B., Taylor M., et al.  Towards cross-Canada monitoring of the unregulated street drug supply. BMC Public Heal. 2021;21(1):1678. doi: 10.1186/s12889-021-11757-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12889-021-11757-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson M., Parmar A., Papamihali K., Weng A., Lock K., Buxton J.A. Investigating opioid preference to inform safe supply services: a cross sectional study. Int. J. Drug Policy. 2022;101 doi: 10.1016/j.drugpo.2021.103574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2021.103574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marchand K., Beaumont S., Westfall J., MacDonald S., Harrison S., Marsh D.C., et al.  Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst. Abus. Treat. Prev. Policy. 2019;14(1):37. doi: 10.1186/s13011-019-0227-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13011-019-0227-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brothers T.D., Bonn M. Patient-centred care in opioid agonist treatment could improve outcomes. CMAJ. 2019;191(17):E460–E461. doi: 10.1503/cmaj.190430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.190430</ArticleId>
            <ArticleId IdType="pmc">PMC6488477</ArticleId>
            <ArticleId IdType="pubmed">32392475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brothers T.D., Fraser J., Webster D. Caring for people who inject drugs when they are admitted to hospital. CMAJ. 2021;193(12):E423–E424. doi: 10.1503/cmaj.202124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.202124</ArticleId>
            <ArticleId IdType="pmc">PMC8096383</ArticleId>
            <ArticleId IdType="pubmed">33753366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimmel S.D., Bazzi A.R., Barocas J.A. Integrating harm reduction and clinical care: lessons from Covid-19 respite and recuperation facilities. J. Subst. Abus. Treat. 2020;118 doi: 10.1016/j.jsat.2020.108103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jsat.2020.108103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuertes R., Belo E., Merendeiro C., Curado A., Gautier D., Neto A., et al.  Lisbon’s COVID 19 response: harm reduction interventions for people who use alcohol and other drugs in emergency shelters. Harm Reduct. J. 2021;18(1):13. doi: 10.1186/s12954-021-00463-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12954-021-00463-x</ArticleId>
            <ArticleId IdType="pmc">PMC7829636</ArticleId>
            <ArticleId IdType="pubmed">33494726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcus T.S., Heese J., Scheibe A., Shelly S., Lalla S.X., Hugo J.F. Harm reduction in an emergency response to homelessness during South Africa’s COVID-19 lockdown. Harm Reduct. J. 2020;17(1):60. doi: 10.1186/s12954-020-00404-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12954-020-00404-0</ArticleId>
            <ArticleId IdType="pmc">PMC7443613</ArticleId>
            <ArticleId IdType="pubmed">32831083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pisani E. Tilting at windmills and the evidence base on injecting drug use. Lancet. 2010;376(9737):226–227. doi: 10.1016/s0140–6736(10)61132–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140–6736(10)61132–4</ArticleId>
            <ArticleId IdType="pubmed">20669403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gostin L.O., Powers M. What does social justice require for the public’s health? Public health ethics and policy imperatives. Health Aff. 2006;25(4):1053–1060. doi: 10.1377/hlthaff.25.4.1053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1377/hlthaff.25.4.1053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeBruin D., Liaschenko J., Marshall M.F. Social justice in pandemic preparedness. Am. J. Public Health. 2012;102(4):586–591. doi: 10.2105/ajph.2011.300483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2105/ajph.2011.300483</ArticleId>
            <ArticleId IdType="pmc">PMC3489368</ArticleId>
            <ArticleId IdType="pubmed">22397337</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
